Insider Selling: Vir Biotechnology (NYSE:VIR) EVP Sells $379,121.00 in Stock

Vir Biotechnology (NYSE:VIR) EVP Herbert Virgin sold 7,900 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $47.99, for a total value of $379,121.00. Following the sale, the executive vice president now directly owns 7,900 shares of the company’s stock, valued at approximately $379,121. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Herbert Virgin also recently made the following trade(s):

  • On Tuesday, July 14th, Herbert Virgin sold 7,900 shares of Vir Biotechnology stock. The shares were sold at an average price of $48.85, for a total value of $385,915.00.
  • On Tuesday, June 23rd, Herbert Virgin sold 5,560 shares of Vir Biotechnology stock. The stock was sold at an average price of $38.99, for a total value of $216,784.40.
  • On Friday, June 19th, Herbert Virgin sold 3,510 shares of Vir Biotechnology stock. The stock was sold at an average price of $38.00, for a total value of $133,380.00.
  • On Tuesday, June 9th, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The stock was sold at an average price of $36.28, for a total value of $138,045.40.
  • On Thursday, May 14th, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The stock was sold at an average price of $30.07, for a total value of $114,416.35.

VIR opened at $47.76 on Friday. The stock has a fifty day simple moving average of $43.63 and a two-hundred day simple moving average of $33.32. Vir Biotechnology has a 12-month low of $11.65 and a 12-month high of $75.00.

Vir Biotechnology (NYSE:VIR) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.18). The business had revenue of $5.72 million during the quarter, compared to analyst estimates of $3.21 million.

VIR has been the subject of a number of research analyst reports. Barclays raised their price target on Vir Biotechnology from $41.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Zacks Investment Research raised Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Wednesday, July 22nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Vir Biotechnology has a consensus rating of “Hold” and a consensus target price of $32.40.

Institutional investors and hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC bought a new position in Vir Biotechnology in the second quarter worth $43,000. Citigroup Inc. boosted its position in shares of Vir Biotechnology by 83.0% during the first quarter. Citigroup Inc. now owns 2,645 shares of the company’s stock valued at $91,000 after buying an additional 1,200 shares during the last quarter. Advisor Group Holdings Inc. purchased a new position in Vir Biotechnology in the first quarter worth about $96,000. Nuveen Asset Management LLC purchased a new position in Vir Biotechnology in the fourth quarter worth about $143,000. Finally, UBS Group AG purchased a new position in Vir Biotechnology in the fourth quarter worth about $150,000.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Read More: Balanced Fund

Insider Buying and Selling by Quarter for Vir Biotechnology (NYSE:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.